

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

July 16, 2007

In re Application of: Tan *et al.*
Serial No. 10/826,098
Filed: April 16, 2004
For: **PHARMACEUTICAL COMPOSITIONS**
Examiner: Cotton, Abigail Manda
Art Unit: 1617
Attorney Docket No.: DIZ-5
Confirmation No.: 9265

RESPONSE TO OFFICE ACTION

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

R E M A R K S

The Office Action of April 16, 2007 has been reviewed and its contents carefully noted. Reconsideration of this case is earnestly requested. Claims 1-16 are pending in the application.

Applicant gratefully acknowledges the Examiner's statement that the rejections under 35 U.S.C. § 112, first and second paragraphs, have been withdrawn, and that Applicant's previous submissions have been entered.

Rejections Under 35 U.S.C. § 103(a)

Claims 1-12 and 15-16 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Khan *et al.* (WO 02/43707) in view of Amey *et al.* (U.S. Pat. No. 6,080,426).

Claims 13-14 stand rejected under 35 U.S.C. 103(a) as being unpatentable over Khan *et al.* (WO 02/43707) in view of Amey *et al.* (U.S. Pat. No. 6,080,426), and further in view of Xiping Wang (U.S. Pat. No. 6,482,432).

Applicant respectfully disagrees, and maintains that the claims 1-16 are patentable over Khan *et al.*, Amey *et al.*, and Wang, both individually and in combination, for the reasons set forth below. Reconsideration and withdrawal of the obviousness rejections of claims 1-16 are therefore earnestly requested.